# S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

> **NCT00410813** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 85 (actual)

## Conditions studied

- Breast Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT00410813
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2013-01
- **Final completion:** 2014-01
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2017-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410813, "S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00410813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*